SEC Comment Letter 0000000000-24-001647 to Apogee Therapeutics, Inc. (APGE) (CIK 0001974640) (APGE)

Apogee Therapeutics, Inc. (APGE) (CIK 0001974640)
Date: Feb. 29, 2024 · CIK: 0001974640 · Accession: 0000000000-24-001647

View on Edgar

AI Filing Summary & Sentiment

Date

February 12, 2024

Author

Not clearly detected

Form

UPLOAD

Company

Apogee Therapeutics, Inc. (APGE) (CIK 0001974640)

Letter

United States securities and exchange commission logo February 12, 2024 Michael Henderson, M.D. Chief Executive Officer Apogee Therapeutics, Inc. 221 Crescent St., Building 17, Suite 102b Waltham, MA 02453 Re:Apogee Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted February 9, 2024 CIK No. 0001974640 Dear Michael Henderson: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melanie E. Neary

Show Raw Text

United States securities and exchange commission logo
February 12, 2024
Michael Henderson, M.D.
Chief Executive Officer
Apogee Therapeutics, Inc.
221 Crescent St., Building 17, Suite 102b
Waltham, MA 02453
Re:Apogee Therapeutics, Inc.
Draft Registration Statement on Form S-1
Submitted February 9, 2024
CIK No. 0001974640
Dear Michael Henderson:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Melanie E. Neary

SecProbe.io